Cargando…
Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center
Background/Aim. To evaluate the clinical efficacy of FOLFOX4 (5-fluomumcil/leucovorin combined and oxaliplatin) neoadjuvant chemotherapy for advanced gastric cancer (AGC). Patients and Methods. Fifty-eight AGC patients were enrolled in this retrospective cohort study, 23 in the neoadjuvant group and...
Autores principales: | Sun, Zhen, Zhu, Rui-Juan, Yang, Gui-Fang, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127276/ https://www.ncbi.nlm.nih.gov/pubmed/25136668 http://dx.doi.org/10.1155/2014/418694 |
Ejemplares similares
-
FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014) -
A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for
locally advanced gastric cancer
por: Wang, Xiang, et al.
Publicado: (2016) -
Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011) -
Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011) -
The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)